Gossamer Bio, Inc.

Gossamer Bio reported an officer departure on May 18, 2026, according to SEC filings monitored by FilingFirehose over the last 90 days. No cyber incidents were detected in the same window, but executive turnover at biotech firms often correlates with financing pressure and equity dilution risk. The full $49 Report extends analysis across 12 months of 8-K filings, quantifies dilution risk scores, maps financing history, and surfaces AI-detected red flags that routine scanning misses. The full $49 Report adds comprehensive context on management stability, capital structure trends, and forward-looking risk signals.